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Abstract
Background: A number of researchers have speculated that neurological disorders are mostly due to the interaction of
common susceptibility genes with environmental, epigenetic and stochastic factors. Genetic factors such as mutations,
insertions, deletions and copy number variations (CNVs) are responsible for only a small subset of cases, suggesting
unknown environmental contaminants play a role in triggering neurological disorders like idiopathic autism. Psychoactive
pharmaceuticals have been considered as potential environmental contaminants as they are detected in the drinking
water at very low concentrations. Preliminary studies in our laboratory identified gene sets associated with neuronal
systems and human neurological disorders that were significantly enriched after treating fish brains with psychoactive
pharmaceuticals at environmental concentrations. These gene expression inductions were associated with changes in fish
behavior. Here, we tested the hypothesis that similar treatments would alter in vitro gene expression associated
with neurological disorders (including autism) in human neuronal cells. We differentiated and treated human
SK-N-SH neuroblastoma cells with a mixture (fluoxetine, carbamazepine and venlafaxine) and valproate (used as a
positive control to induce autism-associated profiles), followed by transcriptome analysis with RNA-Seq approach.
Results: We found that psychoactive pharmaceuticals and valproate significantly altered neuronal gene sets associated
with human neurological disorders (including autism-associated sets). Moreover, we observed that altered expression
profiles in human cells were similar to gene expression profiles previously identified in fish brains.
Conclusions: Psychoactive pharmaceuticals at environmental concentrations altered in vitro gene expression profiles
of neuronal growth, development and regulation. These expression patterns were associated with potential neurological
disorders including autism, suggested psychoactive pharmaceuticals at environmental concentrations might mimic,
aggravate, or induce neurological disorders.
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Background
There are approximately 3000 synthetic chemicals known
to interact with humans through air, water, and food [1, 2].
These chemicals might serve as environmental contami-
nants and trigger neurological disorders, such as autism
spectrum disorders (ASD), in genetically susceptible indi-
viduals [3–5]. Among this diverse group of environmental
contaminants, we focused on pharmaceuticals and per-
sonal care products (PPCPs) due to their tendency to con-
taminate environmental water systems [2]. PPCPs include
psychoactive pharmaceuticals that are highly prescribed in
the United States and other chemicals like bis-phenol A
(BPA) in plastics, phthalates in cosmetics and teratogenic
chemicals [1].
Psychoactive pharmaceuticals like fluoxetine, venlafaxine
and carbamazepine, have been detected in the drinking
water at very low concentrations [2, 6, 7]. These pharma-
ceuticals, some of which are metabolically active and have
relatively long half-lives for over a month, reach waste-
water treatment plants (WWTP) through excretion by
clinical patients [7, 8]. Due to the chemical properties of
these drugs and inefficient filtration of WWTP, these drugs
end up mixing up with the ground water, and thus reach
drinking water at low concentrations [7, 8].
We previously hypothesized that psychoactive pharma-
ceuticals as environmental contaminants alter neuronal
gene expression associated with neurological disorders
like ASD. To determine this, our lab treated juvenile fat-
head minnows (Pimephales promelas) with psychoactive
pharmaceuticals (fluoxetine, venlafaxine and carbamaze-
pine) individually and in mixtures at environmentally
relevant concentrations [2, 6]. After treating them for
15 days, we extracted the brains and carried out micro-
array analysis. Using gene set enrichment analysis (GSEA)
[9], we identified enrichment (up- or down-regulation) of
gene sets associated with neuronal growth, regulation and
development in the juvenile minnow brains in response to
psychoactive drug exposure [2, 6]. We also identified
altered neuronal gene sets associated with neurological
disorders, including ASD [6]. Moreover, fish exposed to
psychoactive pharmaceuticals exposed had an altered
behavioral phenotype [2, 10].
In the present study, we hypothesized that psychoactive
pharmaceuticals (fluoxetine, venlafaxine and carbamaze-
pine) at environmental concentrations would alter in vitro
human neuronal gene expression that is 1) similar to gene
expression profile in fathead minnow, and 2) associated
with neuro-developmental disorders. To determine if al-
tered gene expression profile was associated with idio-
pathic autism, we also treated human neuronal cells with
valproic acid, which is known to induce autism-like phe-
notypes in mice [11]. Identifying altered gene expression
profiles in treated cells and finding a similar pattern with
valproic acid induced gene expression would reveal the
extent to which psychoactive pharmaceuticals at very low
concentrations could induce gene expression associated
with potential neurological disorders like ASD.
Methods
Cell culture and differentiation
Human SK-N-SH cell line was obtained from American
Type Culture Collection (ATCC #HTB-11). Cells were
cultured in Eagle’s Minimum Essential Medium (EMEM;
ATCC). This media was supplemented with 1 % penicillin-
streptomycin-neomycin (Sigma) and 10 % (v/v) fetal bovine
serum (FBS). Retinoic acid (RA; Sigma) was used to induce
SK-N-SH cells [12] to differentiate into more neuron-like
cells [13] because this cell line is a mixture of different cell
types. Approximately 15,000 cells were cultured in T-75
flask (Corning) supplemented with EMEM media for two
days, and then Retinoic acid (10 μM) was added. Cells were
treated with RA for two weeks and media was replaced
every three-four days [12]. Cultures were monitored visu-
ally using light microscopy for morphological changes, and
evaluated for neuronal cell markers (NeuN, PSD95 and
NCAM) during the differentiation process [12, 14].
Pharmaceuticals treatments
Stock solutions (10 mM) of fluoxetine (FLX; Sigma
F133; Active metabolite), venlafaxine (VNX; Sigma
D2069; Active metabolite) and carbamazepine (CBZ;
Sigma C4206; Active metabolite), and 1 mM stock solu-
tion of valproic acid (VPA; Santa Cruz Biotechnology
sc211393; Active metabolite) were prepared in dimethyl
sulfoxide (DMSO). After differentiation for two weeks,
cells were treated with a mixture composed of (MIX:
FLX 10 μg/l; VNX 50 μg/l; CBZ 100 μg/l) [2], and Val-
proate (VPA: 4.9 mg/l) [15]. Control cells were treated
with DMSO (vehicle) only, and the final concentration of
DMSO in the cultures was 0.05 %. To examine if psycho-
active pharmaceuticals in drinking water at environmental
concentrations could induce neuronal gene expression, we
chose to treat neuronal cells with the mixture of three
pharmaceuticals (fluoxetine, carbamazepine and venlafax-
ine). Cells were treated in three replicates with the phar-
maceuticals for 48 h in EMEM media without FBS to
avoid any binding of pharmaceuticals with the serum pro-
teins. All of the treatments were shown not to affect
overall cell viability with respect to control (no treat-
ment), based on the adherent nature of the monolayers
and the result from CyQuant Viability Assay [16]. After
treating cells for 48 h, they were collected with Versene
solution (Gibco).
RNA extraction, cDNA synthesis and sequencing
After 48 h of exposure, cells were collected with trypsin,
centrifuged, and RNA was extracted using Qiagen RNeasy
Plus Mini Kit (74134) according to the manufacturer’s
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protocol. Total RNA concentration was determined using
NanoDrop (Thermo Scientific), and the RNA integrity
value (RIN) was analyzed on Agilent 2100 Bioanalyzer
(Agilent, Santa Clara, CA). RNA was quantified with
Qubit spectrophotometer (Life technologies). Using
Illumina Tru-seq stranded total RNA kit, cDNA library
was prepared in following steps: RiboZero depletion
and fragmentation, first and second strand cDNA synthe-
sis, adenylation of 3′ ends, adapter ligation, PCR amplifi-
cation, library validation using qPCR – Kapa Biosystems
Library Quantification Kit, and normalization and pooling
in preparation for cluster generation on MiSeq. Samples
were then loaded onto flow cell (MiSeq Reagent kit v3
150 cycle) and sequenced on Illumina MiSeq 2 according
to the manufacturer’s instructions.
Bioinformatics data analysis
Quality control, alignment, and read counting
In total, three treatments (mixture, valproate, and con-
trol) with three replicates each were sequenced with five
flow cells using Illumina MiSeq, which generated more
than 10 M paired-end reads for each replicate (refer
Additional file 1). The raw sequences in FASTQ files
underwent quality control analysis using FastQC (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc). All
the samples were sequenced at 75b read length and they
all passed the quality check. We aligned the quality
checked reads to human genome hg19 using TopHat
version 2.0.11 [17]. Most of the reads (~90 %) had aver-
age base quality above Q30. The reference genome se-
quence, the bowtie index files for the reference genome
sequence, and the gene annotation file were downloaded
from Illumina iGenomes project (http://support.illumina.
com/sequencing/sequencing_software/igenome.html). The
number of reads that map to human known genes were
counted by summerizeOverlaps function in GenomicAlign-
ments R package [18]. Only the genes that have at least one
read for all replicates were retained for downstream
analysis.
Analysis of differential gene expression
Differentially expressed genes were identified using DESeq2
version 1.6.1 [19]. Differentially expressed genes from 2
groups (Mixture and Valproate) with respect to the control
treatment were identified.
Gene set enrichment analysis
We used GAGE version 2.14.4 [20] for gene set enrich-
ment analysis. We used GAGE to analyze gene sets that
were analyzed previously in Fish brains [2, 6]. These gene
sets are grouped as Neuronal development, regulation,
growth; Neurological Disorders (ND); Autism spectrum
disorders (ASD) [2, 6]. For extensive analysis, we also ana-
lyzed gene sets from MSigDB ‘C2’ and ‘C5’ (refer
Additional file 2). Enrichment analyses were carried out
using gage function using non-parametric Kolmogorov-
Smirnov tests. We used GAGE package to identify signifi-
cantly enriched (significantly up- and/or down-regulated;
P-value < 0.01 and Q-value < 0.1) gene sets within mixture
and valproate treatments.
Results
Patterns of psychoactive pharmaceuticals – induced in
vitro gene expression in neuronal development, growth
and regulation
We postulated that psychoactive pharmaceuticals at en-
vironmental concentrations would alter gene expression
of neuronal systems. Support for this hypothesis would
suggest that dysregulation of neuronal systems would re-
sult in altered neuronal circuits and may result in fewer
neuronal connections. To address this question we used
differentiated SK-N-SH neuroblastoma cells and treated
them with the mixture (MIX: FLX-10 μg/l; VNX-50 μg/l;
CBZ-100 μg/l), and valproate (VPA: 4.9 mg/l) in repli-
cates of three samples for each treatment.
For the development collection, we observed six enriched
gene sets (significantly down-regulated, P-value < 0.01, Q-
value < 0.1) by MIX treatment. VPA treatment enriched the
expression of seven gene sets (four gene sets down-
and three gene sets up-regulated, Additional file 3).
AXONOGENESIS, REGULATION OF NEUROGENESIS
and SYNAPSE PART gene sets were enriched in both VPA
and MIX treatments. And, SYNAPSE PART gene set was
also enriched (up-regulated) in fish brains.
For the regulation collection, we observed 14 enriched
gene sets (13 gene sets down- and one gene set up-
regulated, P-value < 0.01, Q-value < 0.1) by MIX treatment.
VPA treatment enriched the expression of eight gene sets
(up-regulated, Additional file 3). All eight up-regulated
gene sets in VPA treatment were down-regulated in MIX
treatment. Among those sets, two gene sets (NEURO-
TRANSMITTER_BINDING and SYNAPSE) were also
enriched in fish brains.
For the growth collection, we observed eight enriched
gene sets (all down-regulated, P-value < 0.01, Q-value < 0.1)
by MIX treatment. VPA treatment enriched the expression
of five gene sets (up-regulated, Additional file 3). All five
up-regulated gene sets in VPA treatment were down-
regulated in MIX treatment. Two gene sets (AXON
and NEURON_PROJECTION) were also enriched in
fish brains.
Patterns of psychoactive pharmaceuticals – induced in
vitro gene expression in neurological disorders (ND) and
ASD groups
We then sought to determine if altered in vitro gene ex-
pression was associated with neurological disorders and
ASD. To accomplish this, we analyzed and compared
Kaushik et al. BMC Genomics 2016, 17(Suppl 3):435 Page 279 of 314
the gene expression of already published ND and ASD
gene sets in MIX and VPA treatments.
For the ND collection, we observed six enriched gene
sets (four down- and two up-regulated, P-value < 0.01,
Q-value < 0.1) by MIX treatment. VPA treatment enriched
the expression of three gene sets (two gene sets down-
and one gene set up-regulated, Additional file 3).
AUTISM_IDIOPATHIC and PARKINSONS gene sets
were enriched in both VPA and MIX treatments as
well as in fish brains.
For the ASD collection, we observed two enriched gene
sets (both up-regulated, P-value < 0.01, Q-value < 0.1) by
MIX treatment. VPA treatment enriched the expression
of five gene sets (down-regulated, Additional file 3).
ASD_MILD gene set was enriched in both VPA and
MIX treatments as well as in fish brains.
Ranked gene lists from the mixture and valproate
treatment
We sorted all genes from gene expression profiles in
human neuronal cells treated with the MIX (FLX, VNX,
CBZ) and valproate (VPA). In each treatment, we se-
quenced ~ 17,000 genes and analyzed their expression.
We then ranked them based on their fold change ex-
pression within each treatment. Tables 1 and 2 show,
the 50 most strongly up-and down-regulated genes. We
also reported the fold-change score of genes which
were presented on the fish microarray chip.
Discussion
Comparison between human MIX treatment and fish
gene expression patterns
The results partially supported our first hypothesis that
the MIX treatment on human SK-N-SH cell line induced
gene sets enrichment patterns similar to that of the fish
experiment following mixture treatment, although the
degree of similarity was not high.
Among the neural circuit development gene sets, all
the six significantly enriched gene sets in human neuronal
cells following MIX treatment were enriched in a down-
regulated manner; whereas in the fish experiment, the two
significantly enriched sets were both up-regulated. We do
not know why the direction was opposite, but we do no-
tice that, one gene set, SYNAPSE PART, was enriched in
both treatments [2]. Previous studies have found that al-
tered expression of NCAM, IRX3 and NKX6.1 genes in
SYNAPSE PART change the fate and position of neurons
generated in the chick neural tube [21, 22]. Also within
those down-regulated gene sets contains gene PSD95
(DLG4) and GABA, which have recently been found to be
associated with neurological disorders like autism by al-
tering synaptic assembly [14, 23, 24].
In the growth group, we observed similar patterns
where all enriched sets in MIX treatment were down-
regulated and all those in the fish experiment were up-
regulated. Among those sets, two were enriched in both
treatments, AXON and NEURON PROJECTION. Other
studies have found that genes within these two gene sets
modulate the fate, lineage, and timing of neuronal develop-
ment by playing a critical role in the formation and matur-
ation of neural circuits [23, 25, 26].
In the regulation group, we observed that NEURO-
TRANSMITTER BINDING gene set was down-regulated
in fish brains as well as in human cells [2]. This could be
possible due to the therapeutic effect of fluoxetine (SSRI)
in the mixture treatment [2]. Fluoxetine is known to re-
duce the re-uptake of serotonin by inhibiting monoamine
transporters on the pre-synaptic neuronal membrane
[27, 28]. Due to the longer availability of neurotrans-
mitters in the synaptic cleft, the expression of serotonin
receptors is down-regulated, thus a decrease in neuro-
transmitter binding [29]. Another gene set SYNAPSE
was significantly up-regulated in fish brains [2], but
down-regulated in treated human cells. This gene set
was responsible for modulating wiring of neuronal cir-
cuits by controlling the number of synapse as well as
organization of synaptic assembly and specificity [26, 30].
Altered synaptogenesis has been strongly considered as a
potential mechanism in ASD pathogenesis [31, 32].
Comparison between human MIX and VPA gene
expression patterns
We used valproate (an anticonvulsant) to treat human
neuronal cells as a positive control because prenatal ex-
posure of valproate has been found to be strongly associ-
ated with autism [3] and valproate is known to induce
autism-like phenotypes in mice [11]. Similarly, carbamaze-
pine (presented in the mixture treatment) is a mood
stabilizer and anticonvulsant [11, 33] and it also inhibits
the epileptic effects in the brain by blocking sodium chan-
nels [11, 33]. By and large, the results support our second
hypothesis that the MIX and VPA treatments change the
RNA expression profile in similar ways, albeit in an inter-
esting fashion, since the two treatments often enrich the
same gene sets but in different directions.
In the development group of VPA treatment, we found
four gene sets significantly down-regulated and three
gene sets significantly up-regulated in human neuronal
cells. Three gene sets (AXONOGENESIS, REGULATION
OF NEUROGENESIS and SYNAPSE PART) were enriched
in both mixture and valproate treatments, but in the
opposite direction. Similar to fish gene expression, VPA
treatment up-regulated SYNAPSE PART gene set [2].
This states that VPA exposure might be associated with
disturbed neuronal fate and position [21, 22] as well as
synaptic assembly [1, 22, 34].
In the growth group, we observed that five gene sets
were up-regulated in the VPA treatment. Interestingly,
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Table 1 Ranked gene list from the mixture treatment (50 most up- and down-regulated)
Up-regulated genes Down-regulated genes
Rank Genes Fold change P-value Fold change in fish brains Rank Genes Fold change P-value Fold change in fish brains
1 FAM129A 3.25 0.000 17350 ANGPTL4 −3.36 0.000
2 CACNA2D3 1.99 0.000 0.90 17349 THBS1 −2.19 0.000 0.34
3 NUPR1 1.97 0.002 −0.10 17348 STARD13 −2.17 0.000 −0.46
4 GRM8 1.90 0.000 17347 DRP2 −2.15 0.000
5 PTCHD1 1.89 0.000 17346 TNNT2 −2.11 0.000 −0.23
6 TMEM132C 1.76 0.000 17345 AQP10 −2.10 0.000
7 DDIT3 1.55 0.000 0.73 17344 STRA6 −1.97 0.000 −0.10
8 XKR4 1.53 0.010 17343 PAPPA2 −1.92 0.000
9 CHRNA10 1.33 0.002 17342 NEDD9 −1.88 0.000 −1.21
10 LPHN3 1.24 0.004 17341 GGTA1 −1.85 0.001
11 SERPINF2 1.23 0.008 0.15 17340 SH3TC1 −1.83 0.000
12 NKX3-1 1.22 0.008 17339 ADAMTSL2 −1.80 0.000 −0.25
13 HRK 1.22 0.051 17338 RGS13 −1.78 0.000
14 SCARNA20 1.22 0.009 17337 ANO1 −1.77 0.000
15 PABPC3 1.21 0.006 17336 LOC283731 −1.75 0.000
16 KIT 1.18 0.001 0.15 17335 CMKLR1 −1.73 0.000 0.86
17 KIAA1045 1.18 0.002 −0.12 17334 VIP −1.71 0.000
18 DLL1 1.15 0.013 0.05 17333 HTR2B −1.69 0.000
19 C9orf150 1.12 0.000 17332 RAG2 −1.67 0.004 0.20
20 SNORA14A 1.11 0.164 17331 ACVRL1 −1.67 0.000
21 B3GALT1 1.09 0.134 17330 VCAN −1.66 0.000
22 RIMBP3C 1.09 0.096 17329 C6 −1.65 0.006 −1.11
23 NOS1AP 1.06 0.172 0.37 17328 ENO3 −1.64 0.000 −0.00
24 GLYATL2 1.06 0.021 17327 TM4SF1 −1.63 0.008 0.22
25 STAC2 1.04 0.259 17326 PCTK3 −1.62 0.004
26 CRYBB2 1.04 0.020 0.01 17325 FAM65C −1.60 0.000
27 SLC16A10 1.01 0.167 −0.31 17324 FLJ36208 −1.60 0.000
28 CDH7 1.01 0.031 −0.00 17323 LOC400950 −1.58 0.000
29 MYB 1.01 0.030 −0.17 17322 RARRES3 −1.58 0.000
30 LCA5L 1.00 0.176 17321 SLCO4C1 −1.53 0.000
31 ID4 0.99 0.033 −0.17 17320 PRAP1 −1.52 0.022
32 MALAT1 0.99 0.004 17319 SLC18A1 −1.51 0.000
33 SNAR-A3 0.99 0.230 17318 TFPI2 −1.51 0.000
34 EDN1 0.98 0.033 17317 FBP1 −1.50 0.000 0.43
35 VSTM2A 0.97 0.000 17316 FGL1 −1.49 0.001
36 HERV-FRD 0.97 0.036 17315 COL9A3 −1.48 0.001
37 CNTD1 0.97 0.037 −1.03 17314 LRRTM1 −1.48 0.015 0.25
38 ELL2 0.96 0.000 −0.30 17313 BTK −1.48 0.000 −0.30
39 SLC13A3 0.96 0.027 0.02 17312 SLC24A2 −1.46 0.000 0.11
40 DENND1B 0.96 0.114 0.06 17311 IRF6 −1.45 0.000 0.17
41 CYP2C18 0.95 0.041 17310 LOC392232 −1.45 0.012
42 AMN 0.95 0.041 −0.33 17309 RD3 −1.45 0.000
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the same five sets were all down-regulated in the MIX
treatment. This suggested that both treatments disturbed
the human gene expression in similar pathways despite
the different directions. One gene set NEURON PRO-
JECTION was up-regulated similar to fish brains [2]. In
the regulation group, we noticed similar results. Eight
gene sets were up-regulated in valproate treatment, but
down-regulated in the mixture treatment. From this re-
peating phenomenon of opposite direction enrichment
of the same gene set, we postulate a general pattern
that the three pharmaceuticals (fluoxetine, venlafaxine
and carbamazepine) and valproate dysregulate the same
pathways in different directions. However, more investi-
gation is needed to confirm or disprove this postula-
tion. We also plotted multi-dimensional scaling using
edgeR [35] and observed that mixture treatment sam-
ples were somewhat closer to valproate samples than
control samples (refer Additional file 1). However, MIX
and VPA samples were still apart, confirming that these
two treatments did not exhibit similar response.
Association of human MIX and VPA gene expression
patterns with neurological disorders
To determine the extent to which altered gene expres-
sion in both MIX and VPA treatments were associated
with neurological disorders (including ASD), we exam-
ined the expression of the already-published gene sets
from neurological disorders (ND) and ASD groups in
both treatments. We also compared these to their corre-
sponding expression pattern in fish brains. For ND group,
MIX and VPA treatments altered PARKINSONS and
Autism_Idiopathic gene sets significantly but in different
directions. Interestingly, mixture treatment of human cells
and fish brains up-regulated Autism_Idiopathic gene
set [6]. For another ASD group, MIX treatment up-
regulated two gene sets (ASD_2Class and ASD_Mild)
similar to fish brains [6]. On the other side, VPA treat-
ment down-regulated three gene sets (ASD_2Class,
ASD_Mild, ASD_Savant) in a different direction
compared to the expression in fish brains [6]. These ex-
pression patterns stated that VPA and MIX treatments
of human cells exhibited a similar response to neuro-
logical disorders (including ASD), suggesting a common
induction effect.
Insights into important genes in both MIX and
VPA treatments
We sought to identify important, or novel genes that
were significantly up- and down-regulated in human
neuronal cells treated with MIX and VPA. We gener-
ated ranked lists of genes based on their fold change,
and tabulated the most 50 strongly up- and down-
regulated genes (Table 1 and 2). We also compared
genes from ranked lists with the ones from fish micro-
array data. For MIX treatment, we noticed four genes
(NUPR1, RTL1, THBS1 and HTR2B) which could be
considered important and novel. The thrombospondin
(THBS1) gene plays an important role in synaptogene-
sis in the developing brain [36]. Recent association
studies have found that both rare and common variants
of this gene are associated with autism [36]. Although
this gene was found to be down-regulated by two-fold,
it was up-regulated in fish brains under similar mixture
treatment [2]. Another important gene, HTR2B, which
codes for serotonin receptor 2B, was down-regulated
by ~ two-fold in human cells. Similar serotonin receptor
genes were also found to be down-regulated in fish
brains. Moreover, recent protein studies in our lab
showed that HTR2B protein was down-regulated in the
same mixture (FLX, VNX, CBZ) treatment. This mech-
anism is explained by the drug effect of fluoxetine
(SSRI), which provides more neurotransmitter in the
synaptic cleft, thus reducing serotonin receptors [29].
In the ranked list of genes by valproate (VPA) treat-
ment, we found three genes (VSNL1, PTER and OXTR)
of particular importance. VSNL1 gene, which encodes
for visinin-like protein 1 in humans, modulates neuronal
morphology by controlling the key signaling pathways in
Table 1 Ranked gene list from the mixture treatment (50 most up- and down-regulated) (Continued)
43 NCRNA00087 0.95 0.301 17308 DDC −1.43 0.000
44 FUT9 0.94 0.042 −0.19 17307 PRLHR −1.43 0.008
45 SCGB1D2 0.92 0.047 17306 NOTUM −1.42 0.052 −0.31
46 TRIB3 0.92 0.000 0.67 17305 TMIGD2 −1.41 0.008
47 MYBL1 0.91 0.019 17304 RTL1 −1.40 0.048 −0.40
48 ZNF726 0.91 0.260 17303 P2RX6 −1.40 0.000
49 DLEU1 0.90 0.173 17302 DKK1 −1.39 0.000
50 SLC7A11 0.90 0.309 −0.41 17301 TRIM9 −1.38 0.000
Table representing the list of 50 most up- and down-regulated genes in human neuronal cells treated with the mixture (FLX, VNX, CBZ). Genes were ranked based
on their expression in fold-change in human cells. P-value represents the significance level of the expression change in the mixture treatment than control.
Corresponding fold change of genes in fish brains is also reported in this table, where blank cells represents genes that are not found in the fish
microarray chip
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Table 2 Ranked gene list from the valproate treatment (50 most up- and down-regulated)
Up-regulated genes Down-regulated genes
Rank Genes Fold change P-value Fold change in fish brains Rank Genes Fold change P-value Fold change in fish brains
1 OPRK1 4.03 0.000 −0.29 17673 CMKLR1 −2.81 0.000 0.86
2 NEUROG2 3.55 0.000 17672 ADAMTS2 −2.74 0.000 0.09
3 VSNL1 3.19 0.000 2.84 17671 HIST1H4L −2.67 0.000
4 GALNAC4S-6ST 3.09 0.000 0.96 17670 ELFN1 −2.44 0.000
5 POSTN 2.93 0.000 1.22 17669 COL4A2 −2.39 0.000 −0.42
6 EVX2 2.86 0.000 17668 GREM2 −2.33 0.000
7 SERPINE1 2.69 0.000 −1.45 17667 FLJ45455 −2.32 0.000 0.86
8 ODZ1 2.64 0.000 17666 VCAN −2.31 0.000
9 DRD5 2.34 0.000 −0.23 17665 SOCS3 −2.29 0.000 0.02
10 CSGALNACT1 2.33 0.001 17664 TGFBI −2.27 0.000 −1.11
11 HOXD13 2.31 0.000 17663 C11orf53 −2.26 0.000
12 C3orf57 2.29 0.000 17662 SNAI1 −2.17 0.000 −0.82
13 B3GALT1 2.29 0.000 17661 LOC283480 −2.11 0.000
14 SECTM1 2.28 0.001 17660 ID1 −2.05 0.000 0.23
15 PLAU 2.20 0.001 17659 PPP1R9A −2.03 0.000 −0.05
16 PDE1A 2.19 0.000 17658 LOC646498 −2.02 0.004
17 VIM 2.14 0.000 0.25 17657 RPS16P5 −2.02 0.000
18 MME 2.11 0.000 17656 COL4A1 −1.98 0.000 0.10
19 KCNJ2 2.09 0.000 17655 GLT8D2 −1.98 0.000
20 HS6ST2 2.09 0.000 −0.15 17654 CYP26A1 −1.96 0.000 0.26
21 SNORA42 2.00 0.003 17653 SLC10A1 −1.95 0.004
22 RASEF 1.99 0.000 0.31 17652 PART1 −1.94 0.000
23 APOL6 1.93 0.000 17651 OXTR −1.89 0.000 1.26
24 NCRNA00164 1.91 0.007 17650 PTPLAD2 −1.84 0.007
25 COLQ 1.91 0.000 17649 C9orf131 −1.83 0.001
26 CACNA2D3 1.90 0.000 0.90 17648 FOS −1.80 0.000 −0.63
27 DEGS2 1.90 0.000 17647 C9orf135 −1.79 0.009
28 NHS 1.89 0.000 17646 GLP1R −1.79 0.000
29 PTER 1.89 0.001 0.11 17645 ETS1 −1.79 0.000 −0.79
30 EDIL3 1.87 0.000 −0.41 17644 NXPH3 −1.79 0.000
31 INSM2 1.85 0.000 17643 LOC100128505 −1.79 0.013
32 GFRA3 1.82 0.000 17642 KCTD12 −1.76 0.000 0.49
33 PROKR2 1.82 0.000 17641 ANGPTL4 −1.74 0.000
34 GRM8 1.81 0.001 17640 FOSB −1.73 0.000
35 TLE4 1.79 0.000 17639 MPPED2 −1.72 0.000 −0.62
36 WNT5A 1.77 0.001 −0.38 17638 C11orf92 −1.71 0.003
37 SMOC2 1.77 0.000 −0.26 17637 WDR38 −1.69 0.001
38 VCAM1 1.76 0.014 0.53 17636 GALNT14 −1.68 0.000 0.03
39 FRMD4B 1.74 0.000 0.10 17635 LOC283143 −1.67 0.002
40 PTRF 1.74 0.000 17634 ACCN1 −1.66 0.002
41 DLK1 1.70 0.000 0.69 17633 C14orf53 −1.66 0.002
42 PTCHD1 1.67 0.001 17632 TAPBPL −1.65 0.021
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CNS. This gene was up-regulated by three-fold in the
valproate treatment. We observed similar up-regulation
of this gene in fish brains following mixture (FLX, VNX,
CBZ) treatment. Other studies have recently found the
association of single-nucleotide polymorphisms (SNPs)
in the VSNL1 gene with neurological disorders like
schizophrenia [37]. Another important gene, oxytocin
receptor (OXTR) was found to be down-regulated by
two-fold in human cells treated with valproate (Table 2).
However, this gene was up-regulated in fish brains ex-
posed to the mixture of psychoactive pharmaceuticals
[2]. Moreover, recent protein studies in our lab showed
an increased expression of OXTR in the same cells
treated with carbamazepine and the mixture (FLX, VNX,
CBZ). Other studies have shown that OXTR serves as
an anxiolytic agent by modulating serotonin release in
serotonergic neurons of the raphe nuclei [38].
Conclusions
To investigate the environmental trigger for idiopathic
autism, we focused on psychoactive pharmaceuticals, po-
tential environmental contaminants that have been de-
tected in drinking water. We found that psychoactive
pharmaceuticals altered the gene expression of neuronal
systems in vitro at environmental concentrations. These
altered gene expressions are associated with potential
neurological disorders by playing a key role in the for-
mation, growth and regulation of neurons. Our data sug-
gests that psychoactive pharmaceuticals might disrupt
neuronal connections by altering the gene expression asso-
ciated with neuronal growth, development and regulation.
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